Myriad Genetics, MYGN

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a ...
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
Myriad Genetics has a 1-year low of $9.76 and a 1-year high of $29.30. Myriad Genetics ( NASDAQ:MYGN – Get Free Report ) last issued its earnings results on Tuesday, February 25th.